Next Article in Journal
5-O-Acetyl-Renieramycin T from Blue Sponge Xestospongia sp. Induces Lung Cancer Stem Cell Apoptosis
Previous Article in Journal
Biomolecular Composition and Revenue Explained by Interactions between Extrinsic Factors and Endogenous Rhythms of Saccharina latissima
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 17
Issue 2
10.3390/md17020108
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine D3/D4 Receptors

by
Pradeep Paudel
1,
Su Hui Seong
1,
Sangwook Wu
2,
Suhyun Park
2,
Hyun Ah Jung
3,* and
Jae Sue Choi
1,*
1
Department of Food and Life Science, Pukyong National University, Busan 48513, Korea
2
Department of Physics, Pukyong National University, Busan 48513, Korea
3
Department of Food Science and Human Nutrition, Chonbuk National University, Jeonju 54896, Korea
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2019, 17(2), 108; https://doi.org/10.3390/md17020108
Submission received: 29 December 2018 / Revised: 28 January 2019 / Accepted: 7 February 2019 / Published: 10 February 2019
Browse Figures
Review Reports Versions Notes

Abstract

:
The G protein-coupled receptor (GPCR) family of proteins comprises signaling proteins that mediate cellular responses to various hormones and neurotransmitters, and serves as a prime target for drug discovery. Towards our goal of discovering secondary metabolites from natural sources that can function as neuronal drugs, we evaluated the modulatory effect of eckol on various GPCRs via cell-based functional assays. In addition, we conducted in silico predictions to obtain molecular insights into the functional effects of eckol. Functional assays revealed that eckol had a concentration-dependent agonist effect on dopamine D3 and D4 receptors. The half maximal effective concentration (EC50) of eckol for the dopamine D3 and D4 receptors was 48.62 ± 3.21 and 42.55 ± 2.54 µM, respectively, while the EC50 values of dopamine as a reference agonist for these two receptors were 2.9 and 3.3 nM, respectively. In silico studies revealed that a low binding energy in addition to hydrophilic, hydrophobic, π–alkyl, and π–π T-shaped interactions are potential mechanisms by which eckol binds to the dopamine receptors to exert its agonist effects. Molecular dynamics (MD) simulation revealed that Phe346 of the dopamine receptors is important for binding of eckol, similar to eticlopride and dopamine. Our results collectively suggest that eckol is a potential D3/D4 agonist for the management of neurodegenerative diseases, such as Parkinson’s disease.

1. Introduction

G-protein-coupled receptors (GPCRs) belong to the largest superfamily of cell surface proteins encoded by the human genome, and are valuable molecular targets for drug discovery. Design and implementation of high-throughput GPCR functional assays to identify novel drug candidates is an important aspect of the early drug discovery process because these receptors are involved in human pathophysiology and are also pharmacologically traceable [1]. Although in silico modeling and receptor targeting have superseded in vitro enzyme assays in drug discovery, in vitro enzyme inhibition assays cannot be neglected, and are still employed as a preliminary step in new lead discovery. Advancements in receptor pharmacology have resulted in new approaches for GPCR drug discovery with a high success rate in clinical trials as reported by the FDA (70%, 33% and 25–30% success rates for phase I, II, and III clinical trials for GPCR target families) [1,2].
Dopamine receptors are specific therapeutic targets for Parkinson’s disease (PD), schizophrenia, and drug abuse. These receptors are categorized as Gαs/olf-coupled D1-like (D1 and D5) and Gαi/o-coupled D2-like (D2, D3 and D4) receptors with regard to the stimulatory or inhibitory properties of the secondary messenger, cyclic adenosine monophosphate (cAMP) [3]. Regulation of cAMP production by dopamine receptors modulates protein kinase A (PKA) along with other exchange proteins. PD is characterized by a low level of dopamine, while schizophrenia results from an excess of dopamine. The oral drug levodopa (l-DOPA) is widely used to treat PD. This drug requires metabolic conversion to the active compound, dopamine, to exert its pharmacological effect. However, a dopamine agonist would have great advantages over levodopa. In schizophrenia, the density of the D3 receptor is enhanced by 10%, while that of the D4 receptor is elevated by 600% [4]. Therefore, D3/D4 receptor antagonists are potential therapeutics for schizophrenia, while their agonists are employed in PD. Other GPCRs are also involved in PD and schizophrenia. All five muscarinic acetylcholine receptors (mAChRs; M1‒M5) are expressed in the striatum and play a role in modulating striatal dopamine release [5]. 5-hydroxytryptamine 1A (5-HT1A) receptor stimulation in levodopa-treated PD patients can modulate striatal dopaminergic function, and 5-HT1AR agonists (e.g., Sarizotan) may be useful in the treatment of advanced PD [6]. Interestingly, Egashira et al. [7] reported that the vasopressin V1a receptor (V1aR) plays a critical role in regulating behavior, social recognition, and anxiety-like behavior.
In this modern era of drug discovery, natural products from the marine environment have gained much interest. However, the procurement and manufacture of rare compounds is challenging [8]. Innovations in aquaculture or semi-synthesis are approaches that can potentially address these issues [9].
Eckol is a phlorotannin with a dibenzo-p-dioxin skeleton and a phloroglucinol component that is abundant in brown algae in the family Lessoniaceae. The structural characteristics and impressive biological activities of natural eckol have spurred researchers to focus on synthesizing and modifying novel derivatives of eckol with superior biological activities [10]. Various biological activities of natural eckol have been reported to date. In our previous work concerning natural anti-Alzheimer’s disease (anti-AD) drugs from marine sources [11,12], eckol from Ecklonia stolonifera showed selective inhibition of acetylcholinesterase (AChE) and β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), but not butyrylcholinesterase (BChE). Similarly, as an anti-PD drug, eckol potently inhibited human monoamine oxidase (MAO)-A and moderately inhibited MAO-B [13]. Eckol as a gamma-aminobutyric acid type A–benzodiazepine (GABAA–BZD) receptor ligand had a hypnotic effect in a mouse model [14]. Similarly, in a study conducted by Kang et al. [15], eckol protected murine hippocampus neuronal (HT22) cells against H2O2-induced cell damage. However, its protective effect against Aβ-induced toxicity in PC12 cells was weaker than that of other phlorotannins [16]. Although there are numerous reports of the enzyme inhibitory activity of eckol in PD and its neuroprotective effects against Aβ-induced toxicity, the receptors that eckol potentially modulates in PD have not been investigated. Based on our previous finding that eckol inhibited human monoamine oxidases, we explored its molecular mechanisms by characterizing its modulatory effects on dopamine receptors because of their role in PD. Furthermore, we performed molecular docking and a molecular dynamics simulation to confirm and further strengthen our findings.

2. Results

2.1. Functional G-Protein-Coupled Receptor (GPCR) Assay

The results of cell-based functional GPCR assays conducted to characterize eckol (Figure 1) as an agonist or an antagonist of various receptor types are tabulated in Table 1 and Table 2, respectively. Results showing inhibition or stimulation higher than 50% are considered to represent significant effects of eckol. A concentration-dependent control agonist effect of eckol on dopamine D3 and D4 receptors is presented in Figure 2.
As shown in Table 1, eckol at 25 μM exhibited 10.6 and 36.55% of the control agonist effect on the human dopamine D3 receptor (hD3R) and D4 receptor (hD4R), respectively. Upon increasing the concentration of eckol to 50 μM, the agonist response rose above 50%, giving half maximal effective concentration (EC50) values of 48.62 ± 3.21 and 42.55 ± 2.54 μM for hD3R and hD4R, respectively. However, it did not have an antagonistic effect on these receptors (Table 2). In addition, eckol did not have any modulating effect on the other tested receptors, namely dopamine D1, 5-HT1A, V1A, tachykinin (NK1), and muscarinic (M5) receptors.

2.2. Molecular Docking Study

Molecular docking is an important tool for predicting drug-biomolecular interactions for the rational drug design and discovery. To gain insight into the basis of the hD3R/hD4R agonist activity of eckol, we performed an in silico docking study. Docking study was validated using reference agonists and antagonists of each dopamine receptor. Binding sites and docking scores of eckol for the hD3R and hD4R are tabulated in Table 3, respectively. As shown in Figure 3, eckol bound to the active site cavity of hD3R with a negative binding energy (−6.41 kcal/mol) by forming five H-bond interactions.
Dotted lines with different colors in Figure 3; Figure 4 represent different types of interactions. For instance, H-bond interactions are represented with green dotted lines, hydrophobic interactions with light-purple dotted lines, and orange dotted lines indicate other type of interactions with aromatic rings like π-sulfur and π-cation interactions. Reference D3 modulators formed a salt bridge to the carboxylate of the strongly conserved Asp110 in helix III, and the two hydroxyl moieties of eckol formed two H-bond interactions (O–H) with the hD3R via Asp110. Similarly, an H-bond with His349 in helix VI and a π–lone pair interaction with His349 were observed, which are the prime interacting residues at orthosteric binding site (OBS) of hD3R. In addition, eckol formed H-bond, π–alkyl, and π–sigma interactions with Ile183 in the extracellular loop (ECL) 2 and was engaged in a π–sulfur interaction with Cys114.
Eckol had lower binding energy for hD4R, e (−6.46 kcal/mol) than dopamine (−5.68 kcal/mol), which might be due to four H-bond interactions. As shown in Figure 4C, eckol formed a complex with the OBS of hD4R via H-bond, hydrophobic, and electrostatic interactions.
Two hydroxyl moieties of the phloroglucinol ring formed three H-bond interactions with Tyr192, Val193, and Ser197 in helix V. In addition, a hydroxyl moiety of the dibenzodioxin skeleton in eckol interacted with Asp115 in helix III, which is a crucial residue for drug binding to the receptor. In addition, π–alkyl interactions with Leu187 and Val193, π–π T-shaped interactions with Phe410 and His414, a π–sulfur interaction with Cys119, and a π-cation interaction with His414 were observed; all these residues are conserved OBS residues of hD4R.
Interestingly, eckol interacted with serine residues in helix V, which are important for activation of hD3R/D4R through H-bonds [17]. Molecular docking models for hD3R and hD4R binding with reference ligands are shown in Supplementary Figures S1 and S2.

2.3. Absorption, Distribution, Metabolism, and Excretion (ADME) Prediction

As shown in Table 4, in silico pharmacokinetic parameter prediction by PreADMET indicated a logPo/w value of 2.99. LogPo/w value is generally used as an indicator of the lipophilicity of a compound. Plasma protein binding of eckol was excellent (100%) and it showed moderate human intestinal absorption (55.60%). In addition, in vivo blood–brain barrier (BBB) penetration calculations demonstrated moderate absorption (0.25) by the central nervous system (CNS). Favorable BBB permeability is a crucial factor in the development of CNS-active drugs [18]. Together, these results indicate that eckol has favorable drug-like properties.

2.4. Molecular Dynamics Simulation Study

Molecular dynamics (MD) simulations are important tools to understand the physical basis of the structure and function of biological macromolecules. In addition, MD provides energetic information about protein and ligand interactions, which is very important to understand the structure-function relationship of the target and the essence of protein–ligand interactions and to guide the drug discovery and design process. Starting from the protein-ligand complex (Figure 3C), we performed a molecular dynamics simulation in the presence of a palmitoyl-oleoyl-phosphatidylcholine (POPC) membrane and an explicit water environment (Figure 5A). After an 80 ns productive MD simulation, the interaction of eckol with the binding pocket had changed significantly. In contrast to the docking results, seven water molecules were involved in the interaction with eckol through H-bonds. H-bonds with water molecules changed the interaction pattern of the ligand with the neighboring molecules compared to the docking results. Val107, Cys114, Val189, Ser193, and Cys114 were replaced in the MD simulation results. However, the interaction of eckol with Asp110, Ile183, and His349 seen in the docking study was conserved in the MD simulation. Two new residues interacted with eckol in the MD simulation: Ser192 and Phe346. Ser192 had an H-bond interaction with eckol with a distance of 2.82 Å. Phe346 had a hydrophobic interaction with eckol. The benzene ring of Phe346 and the benzene ring of eckol had a π–π interaction. The relative configuration of Phe346 with respect to eckol is shown in Figure 6A. Phe346 interacts hydrophobically with eticlopride and dopamine, which contributes to stabilization of the ligand inside the binding pocket through π–π interactions (Table 3). The root mean squared deviation (RMSD) values for the protein backbone and eckol are shown in Figure 6B. The gradual increase in the protein backbone RMSD was consistent with the abrupt increase in the RMSD value of eckol molecule after 60 ns (denoted by the vertical dotted line). From the viewpoint of an “induced-fit” model, the conformation of the protein changed significantly after the orientation of eckol in the binding pocket became optimal for binding interactions to occur.
Binding of Phe346 to eckol appeared to be the main cause of the protein conformational change induced by eckol binding. The bond distance between the center of mass of the benzene ring of Phe346 and the center of mass of one of the benzene rings was measured (shown in Figure 6C and inset). The distance fluctuated around 7 Å for up to 60 ns. The distance between Phe346 and eckol, however, showed a distinct transition to lower values after 60 ns (denoted by the vertical dotted line), implying that Phe346 approached eckol, resulting in greater stabilization of eckol inside the binding pocket. The distance fluctuated around 5.6 ± 0.6 Å after 60 ns. The distribution of this distance (Phe346-ligand) after 60 ns is shown as a histogram (Figure 6D).

3. Discussion

Effective neuronal communication is vital for sensory perception, signal transduction, processing, and motor output in vertebrates through the secretion of neurotransmitters (NTs) at chemical synapses and/or through the direct transfer of intercellular signals via gap junctions at electrical synapses. As electrical coupling is very rare in the vertebrate CNS, neuronal communication relies on the release of a wide variety of NTs: (1) classical NTs (acetylcholine, adenosine, adenosine-triphosphate, glutamate, γ-aminobutyric acid, and glycine) released by Ca2+-triggered exocytosis that allow rapid neuronal communication; (2) monoaminergic NTs (adrenaline, noradrenaline, dopamine, histamine, and serotonin) that are also released by Ca2+-dependent exocytosis from axon terminals and diffuse over longer distances; (3) neuropeptides that undergo Ca2+-dependent exocytosis; and (4) membrane-permeable mediators (nitric oxide, endocannabinoids, other lipid NTs) that are released immediately after synthesis but are not stored in vesicles [19]. NTs, once released, bind to and activate receptors on postsynaptic membranes, and regulate various biochemical signaling cascades. GPCRs are the largest family of membrane proteins and more than 90% of them are expressed in the brain and are critical for normal brain functions [20]. Under- or over-activity of many individual GPCR systems in the brain may contribute to pathological conditions ranging from hypodopaminergic movement disorders to mania and depression. Hence, modulation of GPCR activity is considered a promising strategy for neuronal drug discovery.
Multiple target interactions of a single drug via polypharmacology is regarded as a novel strategy to treat complex diseases like PD and schizophrenia. Familiarity with the structural basis for GPCR drug selectivity can lead to new drug discovery insights. Most available antidepressant drugs at present are based on fortuitous discoveries in the 1950s and act via monoamine neurotransmitters. To date, numerous neuronal drugs (mostly enzyme inhibitors), either synthesized or from natural sources, have been discovered, and many have been approved by the Food and Drug Administration (FDA). However, the failure of some approved drugs to pass clinical trials has prompted researchers to search for new drugs that are both safe and efficacious. Dopamine D2-like receptor agonists are used in the management of PD, dyskinesis, hyperprotactinemia, and restless leg syndrome [21]. l-DOPA, a pro-drug for dopamine, exhibits minor selectivity among D2, D3, and D4 subtypes. This was further supported by functional and radioligand binding assays for dopamine mimetics pramipexole, rotigotine, ropinirole, and pergolide that showed weak preference for the agonist-labeled high-affinity states of D3 and D4 compared to the D2 subtype [22,23]. In our previous report [13], eckol exhibited good inhibition of MAO enzymes. We performed this study to determine the effect of eckol on various GPCRs.
Cell-based functional assays were conducted to characterize eckol as an agonist or an antagonist of various receptors involved in PD. Different reference agonists and antagonists were included in the study to validate our findings. Eckol was found to be an agonist of the hD3R and hD4R. This implies that when the level of dopamine is low (PD state), eckol could bind to these two receptors, activate them, and regulate their downstream signaling, thereby maintaining normal neuronal communication. Among the seven receptors we tested that are to some extent related to PD, eckol had a selective agonist effect only on the hD3R and hD4R. To evaluate the mechanism of receptor binding, computational prediction of how eckol binds to the hD3R and hD4R was conducted using the AutoDock 4.2 program. Eckol fits well into the OBS of human dopamine D3/D4 receptors including ECL2 and helices III, V, and VI (Figure 2A and Figure 3A). The salt bridge to the carboxylate group of the strongly conserved Asp110 of hD3R and Asp115 of hD4R is pharmacologically critical for high-affinity ligand binding to dopaminergic receptors [17]. Even though eckol did not form a salt bridge, it formed an H-bond (O–H) interaction with Asp110 of hD3R and Asp115 of hD4R, respectively. MD simulation using the docking structure of the protein-ligand complex as the initial structure was performed in a more realistic environment with a lipid membrane and explicit water molecules. This demonstrated that the conformational change of the protein was strongly coupled to the conformational change of the eckol molecule inside the binding pocket. In particular, MD simulation analysis (RMSD values and distance) suggested that binding of Phe346 to eckol induced a conformational change in the protein and ligand inside the binding pocket. MD simulation also revealed that Phe346, in addition to binding to eckol, also binds to etclopride and dopamine. Kortagere et al. [24] demonstrated that Ser192 of helix V is important for the activation of D3R. In addition, conserved serine residues in helix V are molecular determinants for agonist-induced signaling from dopamine receptors [25,26]. In our in silico molecular docking and MD study, a H-bond interaction was observed between Ser192 of hD3R (Ser197 of hD4R) and a hydroxyl moiety of eckol. These results are consistent with our experimental data and imply that eckol could play a role as a dual hD3/D4R agonist. In addition, eckol’s pharmacokinetic behavior was analyzed in silico. ADME prediction data showed that eckol is likely to be moderately absorbed in the intestine and penetrate the CNS. Together, the molecular docking results and predicted ADME properties suggest that eckol may be a potent anti-neurodegenerative drug for targeting D3R/D4R.
Dopaminergic receptors mediate the physiological effects of dopamine and the effect differs with structures among the subtypes. The D1-like receptors are positively coupled to adenylyl cyclase (AC) that induce intracellular cAMP accumulation and activates the protein kinase dependent of cAMP (PKA). However, D2-like dopamine receptors are coupled to AC negatively and hence, their activation decrease cAMP level thereby modulating the activity of PKA and its effectors. Through an in vitro human recombinant CHO cell-based functional assays, we characterized eckol as D3R and D4R agonist correlating to cAMP level upon treatment with eckol. Therefore, binding eckol to dopamine receptors inhibits AC and reduces cellular cAMP level by inhibiting inositol triphosphate (IP3)-dependent release of intracellular Ca2+. cAMP is an important and ubiquitous second messenger for many signaling pathways and can influence various effectors, such as protein kinase A (PKA) and dopamine- and cAMP-regulated phosphoprotein (DARPP-32) [27]. Inhibition of Ca2+ channels concomitantly activates K+ channels, and increased K+ conductance leads to hyperpolarization which is responsible for the abolition of Ca2+ action potential [28]. When D2-type dopamine receptors are stimulated, the level of PKA activation reduces as a result the phosphorylation of DARPP-32 at threonine 34 [29].
Dopamine D3 receptors activate the MAPK pathway in CHO cells stably transfected with hD3 receptors via activation of PI3-kinase and an atypical isoform of PKC [30]. In previous reports, eckol through MAPK and PI3k/Akt signaling attenuated oxidative stress by activating Nrf2-mediated HO-1 induction and protected Chinese hamster lung fibroblast from hydrogen peroxide-induced cell damage [31]. Similarly, eckol suppressed stemness and malignancies in glioma stem-like cells by inhibiting both the PI3k-Akt and MAPK signaling [32], and these pathways were previously found to be activated in cancer stem-like cells [33,34]. Interestingly, the p38 MAPK and PI3K/Akt cascades are misregulated in PD and targeting these pathways can offer therapeutic windows for the rectification of aberrant DA neuronal dynamics in PD brains [35]. Therefore, dopamine D3 agonist effect of eckol might be regulated through the MAPK and PI3k-Akt pathway.
D4 receptors can activate the ERK cascade in CHO cells which is dependent on trans-activating the platelet-derived growth factor (PDGF)β receptor, a receptor tyrosine kinase (RTK) [36]. In a recent study by Wang et al. [37], D4 receptor transactivated intracellular PDGFβ receptors indicating an important role for RTKs in the regulation and communication of dopamine and glutamate signaling in the CNS. Interestingly, D4 receptors and reduced glutamate signaling have been implicated in neurological disorders that affect cognition and attention, such as schizophrenia and ADHD [38]. Altogether, the pharmacological effect of eckol as dual hD3/D4R agonist might be attributed to involvement of these well-known cascade mechanisms. Furthermore, in vivo and cell-signaling studies which are essential to warrant these mechanisms are underway, which will be reported in the near future.

4. Materials and Methods

4.1. Material

The transfected Chinese hamster ovary (CHO) cells, rat basophil leukemia (RBL) cells, U373 cells and BA/F3 cells were obtained from Eurofins Scientific (Le Bois I’Eveque, France). Various buffers namely Hank’s balanced salt solution (HBSS) buffer, Dulbecco’s modified Eagle medium (DMEM) buffer and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer were obtained from Invitrogen (Carlsbad, CA, USA). The reference agonists and/or antagonists atropine sulphate salt, acetylcholine chloride, [Sar9, Met(O2)11]-Substance P, [Arg8]-vasopressin (AVP), (+)butacamol, clozapine, dopamine, [d(CH2)5 1, Tyr(Me)2]-AVP, serotonin, SCH 2330, L-733,060, (S)-WAY-100635 and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma-Aldrich (St. Louis, MO, USA). All the other chemicals and reagents used were purchased from E. Merck, Fluka (Rupert-Mayer-Str., Munich, Germany), and Sigma-Aldrich (St. Louis, MO, USA), unless otherwise stated, and were of highest grade available.

4.2. Isolation of Eckol

Eckol was isolated from the leafy thalli of E. stolonifera as described in our previous paper [39]. The chemical structure of eckol is shown in Figure 1.

4.3. Functional GPCR Assay

A functional GPCR cell-based assay presents readouts of multiple second messengers including cAMP for Gi and Gs-coupled receptors and IP1 and IP3/calcium flux for Gq-coupled receptors. Functional assays were conducted at Eurofins Cerep (Le Bois I’Eveque, France) using transected cells expressing human cloned receptors. The in-house functional assay protocol (https://www.eurofinsdiscoveryservices.com/cms/cms-content/services/in-vitro-assays/gpcrs/functional/) and experimental conditions are shown in Supplementary Table S1. Stable cell lines expressing recombinant GPCRs were used in this study.

4.4. Measurement of cAMP Level

In brief, a plasmid containing the GPCR gene of interest (dopamine D1, D3, or D4) was transfected into Chinese hamster ovary (CHO) cells. The resulting stable transfectants (CHO-GPCR cells line) were suspended in HBSS buffer (Invitrogen, Carlsbad, CA, USA) supplemented with 20 mM HEPES buffer and 500 μM IBMX, then distributed into microplates at a density of 5 × 103 cells/well and incubated for 30 min at room temperature in the absence (control) or presence of eckol (25 and 50 μM) or reference agonist. Following incubation, cells were lysed and a fluorescence acceptor (D2-labeled cAMP) and fluorescence donor (anti-cAMP antibody with europium cryptate) were added. After 60 min at room temperature, fluorescence transfer was measured at λex = 337 nm and λem = 620 and 665 nm using a microplate reader (Envison, Perkin Elmer, Waltham, MA, USA). Cyclic AMP concentration was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio). Results are expressed as a percentage of the control response to dopamine for the agonist effect and as a percent inhibition of the control response to dopamine. The standard reference control was dopamine, which was tested in each experiment at several concentrations to generate a concentration-response curve from which its EC50 value was calculated.

4.5. Measurement of Intracellular [Ca2+] Level

The method used to quantify the intracellular [Ca2+] level varied slightly according to receptor type. However, in general, cells expressing different receptors (Table 1) were transfected with an expression vector encoding a receptor polypeptide and were allowed to grow for a time period sufficient for that receptor to be expressed. A fluorescent probe (Fluo8 Direct, Invitrogen, Carlsbad, CA, USA) mixed with probencid in HBSS buffer (Invitrogen, Carlsbad, CA, USA) supplemented with 20 M HEPES (Invitrogen) (pH 7.4) was then added to each well and allowed to equilibrate with the cells for 60 min at 37 °C. Thereafter, assay plates were positioned in a microplate reader (CellLux, PerkinElmer, Waltham, MA, USA) and eckol (25 and 50 μM), reference agonist, or HBSS buffer (basal control) were added, and measurements of the change in fluorescence intensity, which varies proportionally to the free cytosolic Ca2+ ion concentration, were taken. Standard reference control (agonist and antagonist) values are presented in Table 1, and controls were included in each experiment at several concentrations to generate a concentration-response curve from which to calculate EC50 values.
Cellular agonist effect was calculated as the percentage of the control response to a known reference agonist for each target and the cellular antagonist effect was calculated as the percentage inhibition of the control reference agonist response for each target. Results are expressed as a percentage of control agonist response or inverse agonist response (measured response/control response × 100) and as percent inhibition of control agonist response [100 − (measured response/control response × 100)] obtained in the presence of the eckol.

4.6. Molecular Docking Study

Docking of the target receptor and eckol was successfully simulated using AutoDock 4.2 [40]. X-ray crystallographics of a human dopamine D3 receptor (hD3R)-eticlopride complex (PDB ID: 3PBL) and human dopamine D4 receptor (hD4R)-nemonapride complex (PDB ID: 5WIU) were obtained from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB); the resolution of these complexes is 2.89 and 1.96 Å, respectively [3,17]. The 3D structures of eckol, dopamine, eticlopride, (+)-butaclamol, and CHEMBL332154 were obtained from PubChem Compound (National Center for Biotechnology Information), with compound identification numbers (CIDs) of 145937 681, 57267, 37459, and 9926143, respectively. Automated docking simulations were performed using AutoDockTools (ADT) to assess appropriate binding orientations. For the docking calculations, Gasteiger charges were added by default, rotatable bonds were set by ADT, and all torsions were allowed to rotate. Grid maps were generated by AutoGrid. The docking protocol for rigid and flexible ligand docking consisted of 20 independent genetic algorithms; the other parameters used were the ADT defaults. The results were visualized and analyzed using Discovery Studio (v17.2, Accelrys, San Diego, CA, USA) and PyMOL (v1.7.4, Schrödinger, LLC, New York, NY, USA).

4.7. ADME Prediction

Pharmacokinetic parameters of eckol such as absorption, distribution, metabolism, and excretion (ADME) was determined using the web-based software PreADMET (v2.0, YONSEI University, Seoul, Korea) [41].

4.8. Molecular Dynamics Simulation

We performed molecular dynamics (MD) simulations for the dopamine D3 receptor-eckol complex generated by the docking study employing the NAMD 2.9 package [42] with the CHARMM 27 [43] force field and protein and lipid parameters incorporating CMAP terms [44]. Parameters for eckol were retrieved from SwissParam [45]. The protein–ligand complex was embedded in a palmitoyl-oleoyl-phosphatidylcholine (POPC) lipid bilayer with dimensions of 100 Å × 100 Å. The TIP3P water model was employed [46]. Positions for Na+ and Cl− ions were generated with a condition of 5 Å between ions employing the AUTOIONIZE module of visual molecular dynamics (VMD) to approximate 150 mM NaCl in the system [47]. We performed energy minimization over 10,000 steps using the conjugate gradient method. The system was heated to 300 K over 60 ps. The simulation was performed with the constraint that the initial docking position was maintained for 25 ns. The constraint (2 kcal/mol/Å2) was set to decrease gradually during 25 ns. Subsequently, NPnAT ensemble simulations were performed for 80 ns without constraint on the protein (300 K, 1 atm). Constant pressure (1 atm) was maintained by using the Langevin piston Nose-Hoover method [48]. The particle mesh Ewald (PME) method was used for electrostatic interactions [49]. The damping coefficient was 1 ps−1 for Langevin dynamics and the direct space cut off was 12 Å. The simulation was performed with a 2-fs time interval.

4.9. Statistics

All redsults are expressed as the mean ± standard deviation (SD) of triplicate experiments. Statistically significant values were compared using one-way analysis of variance (ANOVA) and Duncan’s test (Systat Inc., Evanston, IL, USA). Different alphabet letters indicate a significant difference between groups at p < 0.05.

5. Conclusions

Eckol is a phlorotannin that is abundant in brown algae and that has a wide variety of biological activities. In the present study, we evaluated the effect of eckol on GPCRs. Cell-based functional assays revealed that eckol is an agonist of the dopamine D3 and D4 receptors. Similarly, in silico modeling and MD simulation suggested the mechanisms by which eckol bound to these receptors and exerted its agonist effect. Overall results of this study suggest that eckol is a D3/D4 agonist that has potential in the management of neurodegenerative diseases, especially PD.

Supplementary Materials

The following are available online at https://www.mdpi.com/1660-3397/17/2/108/s1, Figure S1: Molecular docking models for D3R binding with positive controls, dopamine (A), reported agonist rotigotine (B), reported antagonists eticlopride (C) and (+)-butaclamol (D), Figure S2: Molecular docking models for D4R binding with positive controls, dopamine (A), reported agonist nemonapride (B), and reported antagonist CHEMBL332154 (C), Table S1: Experimental conditions for cell-based functional assays.

Author Contributions

P.P. participated in the design of the study, treatment and biochemical analysis, drafted the manuscript. S.H.S. performed the molecular docking studies and wrote part of manuscript, S.W. and S.P. conducted molecular dynamics and wrote part of manuscript, H.A.J. involved in isolation and spectral analysis, wrote part of the manuscript. J.S.C. conceived the study, coordinated the study, and interpreted the data. All authors read and approved the final manuscript.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (2012R1A6A1028677).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hauser, A.S.; Attwood, M.M.; Rask-Andersen, M.; Schiöth, H.B.; Gloriam, D.E. Trends in GPCR drug discovery: New agents, targets and indications. Nat. Rev. Drug Discov. 2017, 16, 829–842. [Google Scholar] [CrossRef] [PubMed]
  2. Hauser, A.S.; Chavali, S.; Masuho, I.; Jahn, L.J.; Martemyanov, K.A.; Gloriam, D.E.; Babu, M.M. Pharmacogenomics of GPCR drug targets. Cell 2018, 172, 41–54. [Google Scholar] [CrossRef] [PubMed]
  3. Wang, S.; Wacker, D.; Levit, A.; Che, T.; Betz, R.M.; McCorvy, J.D.; Venkatakrishnan, A.; Huang, X.-P.; Dror, R.O.; Shoichet, B.K. D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 2017, 358, 381–386. [Google Scholar] [CrossRef] [PubMed]
  4. Seeman, P.; Van Tol, H.H. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 1994, 15, 264–270. [Google Scholar] [CrossRef]
  5. Zhang, W.; Yamada, M.; Gomeza, J.; Basile, A.S.; Wess, J. Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1–M5 muscarinic receptor knock-out mice. J. Neurosci. 2002, 22, 6347–6352. [Google Scholar] [CrossRef] [PubMed]
  6. Bara-Jimenez, W.; Bibbiani, F.; Morris, M.J.; Dimitrova, T.; Sherzai, A.; Mouradian, M.M.; Chase, T.N. Effects of serotonin 5-HT1A agonist in advanced Parkinson’s disease. Mov. Disord. 2005, 20, 932–936. [Google Scholar] [CrossRef] [PubMed]
  7. Egashira, N.; Tanoue, A.; Matsuda, T.; Koushi, E.; Harada, S.; Takano, Y.; Tsujimoto, G.; Mishima, K.; Iwasaki, K.; Fujiwara, M. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice. Behav. Brain Res. 2007, 178, 123–127. [Google Scholar] [CrossRef]
  8. Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural products. Nat. Rev. Drug Discov. 2009, 8, 69–85. [Google Scholar] [CrossRef]
  9. Mendola, D. Drugs from the Sea; Kargel: Basilea, Switzerland, 2000; pp. 120–133. [Google Scholar]
  10. Shin, H.-C.; Hwang, H.; Park, K.Y.; Kim, S.H.; Lee, H. Eckol Derivatives, Methods of Synthesis and Uses Thereof. U.S. Patent No. 20180127392A1, 10 May 2018. [Google Scholar]
  11. Yoon, N.Y.; Chung, H.Y.; Kim, H.R.; Choi, J.S. Acetyl- and butyrylcholinesterase inhibitory activities of sterols and phlorotannins from Ecklonia stolonifera. Fish. Sci. 2008, 74, 200–207. [Google Scholar] [CrossRef]
  12. Jung, H.A.; Oh, S.H.; Choi, J.S. Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg. Med. Chem. Lett. 2010, 20, 3211–3215. [Google Scholar] [CrossRef]
  13. Jung, H.A.; Roy, A.; Jung, J.H.; Choi, J.S. Evaluation of the inhibitory effects of eckol and dieckol isolated from edible brown alga Eisenia bicyclis on human monoamine oxidases A and B. Arch. Pharm. Res. 2017, 40, 480–491. [Google Scholar] [CrossRef] [PubMed]
  14. Cho, S.; Yang, H.; Jeon, Y.-J.; Lee, C.J.; Jin, Y.-H.; Baek, N.-I.; Kim, D.; Kang, S.-M.; Yoon, M.; Yong, H.; et al. Phlorotannins of the edible brown seaweed Ecklonia cava Kjellman induce sleep via positive allosteric modulation of gamma-aminobutyric acid type A–benzodiazepine receptor: A novel neurological activity of seaweed polyphenols. Food Chem. 2012, 132, 1133–1142. [Google Scholar] [CrossRef] [PubMed]
  15. Kang, S.-M.; Cha, S.-H.; Ko, J.-Y.; Kang, M.-C.; Kim, D.; Heo, S.-J.; Kim, J.-S.; Heu, M.S.; Kim, Y.-T.; Jung, W.-K.; et al. Neuroprotective effects of phlorotannins isolated from a brown alga, Ecklonia cava, against H2O2-induced oxidative stress in murine hippocampal HT22 cells. Environ. Toxicol. Pharmacol. 2012, 34, 96–105. [Google Scholar] [CrossRef] [PubMed]
  16. Ahn, B.R.; Moon, H.E.; Kim, H.R.; Jung, H.A.; Choi, J.S. Neuroprotective effect of edible brown alga Eisenia bicyclis on amyloid beta peptide-induced toxicity in PC12 cells. Arch. Pharm. Res. 2012, 35, 1989–1998. [Google Scholar] [CrossRef] [PubMed]
  17. Chien, E.Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G.W.; Hanson, M.A.; Shi, L.; Newman, A.H.; Javitch, J.A.; Cherezov, V. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330, 1091–1095. [Google Scholar] [CrossRef] [PubMed]
  18. Ajay; Bemis, G.W.; Murcko, M.A. Designing libraries with CNS activity. J. Med. Chem. 1999, 42, 4942–4951. [Google Scholar] [CrossRef]
  19. Huang, Y.; Thathiah, A. Regulation of neuronal communication by G protein-coupled receptors. FEBS Lett. 2015, 589, 1607–1619. [Google Scholar] [CrossRef]
  20. Gainetdinov, R.R.; Premont, R.T.; Bohn, L.M.; Lefkowitz, R.J.; Caron, M.G. Desensitization of G protein–coupled receptors and neuronal functions. Annu. Rev. Neurosci. 2004, 27, 107–144. [Google Scholar] [CrossRef]
  21. Löber, S.; Hübner, H.; Tschammer, N.; Gmeiner, P. Recent advances in the search for D3- and D4-selective drugs: Probes, models and candidates. Trends Pharmacol. Sci. 2011, 32, 148–157. [Google Scholar] [CrossRef]
  22. Levant, B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49, 231–252. [Google Scholar]
  23. Prante, O.; Dörfler, M.; Gmeiner, P. Dopamine receptor subtype-selective drugs: D2-like receptors. In The Dopamine Receptors, 2nd ed.; Springer: Totowa, NJ, USA, 2010; pp. 101–135. [Google Scholar]
  24. Kortagere, S.; Cheng, S.-Y.; Antonio, T.; Zhen, J.; Reith, M.E.; Dutta, A.K. Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies. Biochem. Pharmacol. 2011, 81, 157–163. [Google Scholar] [CrossRef] [PubMed]
  25. Wiens, B.L.; Nelson, C.S.; Neve, K.A. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: Evidence for multiple, agonist-specific active conformations. Mol. Pharmacol. 1998, 54, 435–444. [Google Scholar] [CrossRef] [PubMed]
  26. Javitch, J.A.; Ballesteros, J.A.; Weinstein, H.; Chen, J. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. Biochemistry 1998, 37, 998–1006. [Google Scholar] [CrossRef] [PubMed]
  27. Hemmings, H.C., Jr.; Greengard, P.; Tung, H.L.; Cohen, P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 1984, 310, 503. [Google Scholar] [CrossRef] [PubMed]
  28. Vallar, L.; Meldolesi, J. Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol. Sci. 1989, 10, 74–77. [Google Scholar] [CrossRef]
  29. Beaulieu, J.-M.; Gainetdinov, R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63, 182–217. [Google Scholar] [CrossRef] [PubMed]
  30. Cussac, D.; Newman-Tancredi, A.; Pasteau, V.; Millan, M.J. Human dopamine D3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol. Pharmacol. 1999, 56, 1025–1030. [Google Scholar] [CrossRef]
  31. Kim, K.C.; Kang, K.A.; Zhang, R.; Piao, M.J.; Kim, G.Y.; Kang, M.Y.; Lee, S.J.; Lee, N.H.; Surh, Y.-J.; Hyun, J.W. Up-regulation of Nrf2-mediated heme oxygenase-1 expression by eckol, a phlorotannin compound, through activation of Erk and PI3K/Akt. Int. J. Biochem. Cell Biol. 2010, 42, 297–305. [Google Scholar] [CrossRef]
  32. Hyun, K.-H.; Yoon, C.-H.; Kim, R.-K.; Lim, E.-J.; An, S.; Park, M.-J.; Hyun, J.-W.; Suh, Y.; Kim, M.-J.; Lee, S.-J. Eckol suppresses maintenance of stemness and malignancies in glioma stem-like cells. Toxicol. Appl. Pharmacol. 2011, 254, 32–40. [Google Scholar] [CrossRef]
  33. Hambardzumyan, D.; Becher, O.J.; Rosenblum, M.K.; Pandolfi, P.P.; Manova-Todorova, K.; Holland, E.C. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008, 22, 436–448. [Google Scholar] [CrossRef]
  34. Bleau, A.-M.; Hambardzumyan, D.; Ozawa, T.; Fomchenko, E.I.; Huse, J.T.; Brennan, C.W.; Holland, E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4, 226–235. [Google Scholar] [CrossRef] [PubMed]
  35. Jha, S.K.; Jha, N.K.; Kar, R.; Ambasta, R.K.; Kumar, P. p38 MAPK and PI3K/AKT signalling cascades in Parkinson’s disease. Int. J. Mol. Cell. Med. 2015, 4, 67–86. [Google Scholar]
  36. Oak, J.N.; Lavine, N.; Van Tol, H.H. Dopamine D4 and D2L receptor etimulation of the mitogen-activated protein kinase pathway is dependent ontrans-activation of the platelet-derived growth factor receptor. Mol. Pharmacol. 2001, 60, 92–103. [Google Scholar] [CrossRef] [PubMed]
  37. Wang, C.; Buck, D.C.; Yang, R.; Macey, T.A.; Neve, K.A. Dopamine D2 receptor stimulation of mitogen-activated protein kinases mediated by cell type-dependent transactivation of receptor tyrosine kinases. J. Neurochem. 2005, 93, 899–909. [Google Scholar] [CrossRef] [PubMed]
  38. Ferguson, S.S. Receptor tyrosine kinase transactivation: fine-tuning synaptic transmission. Trends Neurosci. 2003, 26, 119–122. [Google Scholar] [CrossRef]
  39. Jung, H.A.; Jin, S.E.; Ahn, B.R.; Lee, C.M.; Choi, J.S. Anti-inflammatory activity of edible brown alga Eisenia bicyclis and its constituents fucosterol and phlorotannins in LPS-stimulated RAW264.7 macrophages. Food Chem. Toxicol. 2013, 59, 199–206. [Google Scholar] [CrossRef] [PubMed]
  40. Goodsell, D.S.; Morris, G.M.; Olson, A.J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996, 9, 1–5. [Google Scholar] [CrossRef]
  41. Kumar, A.; Srivastava, G.; Srivastava, S.; Verma, S.; Negi, A.S.; Sharma, A. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: Molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer’s disease. J. Mol. Model. 2017, 23, 239. [Google Scholar] [CrossRef]
  42. Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26, 1781–1802. [Google Scholar] [CrossRef]
  43. MacKerell, A.D., Jr.; Banavali, N.; Foloppe, N. Development and current status of the CHARMM force field for nucleic acids. Biopolymers 2000, 56, 257–265. [Google Scholar] [CrossRef]
  44. Mackerell, A.D., Jr.; Feig, M.; Brooks, C.L., III. Extending the treatment of backbone energetics in protein force fields: Limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem. 2004, 25, 1400–1415. [Google Scholar] [CrossRef] [PubMed]
  45. Zoete, V.; Cuendet, M.A.; Grosdidier, A.; Michielin, O. SwissParam: A fast force field generation tool for small organic molecules. J. Comput. Chem. 2011, 32, 2359–2368. [Google Scholar] [CrossRef] [PubMed]
  46. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926–935. [Google Scholar] [CrossRef]
  47. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33–38. [Google Scholar] [CrossRef]
  48. Feller, S.E.; Zhang, Y.; Pastor, R.W.; Brooks, B.R. Constant pressure molecular dynamics simulation: The Langevin piston method. J. Chem. Phys. 1995, 103, 4613–4621. [Google Scholar] [CrossRef]
  49. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N log (N) method for Ewald sums in large systems. J. Chem. Phys. 1993, 98, 10089–10092. [Google Scholar] [CrossRef]
Marinedrugs 17 00108 g001 550
Figure 1. Structure of eckol isolated from Ecklonia stolonifera.
Figure 1. Structure of eckol isolated from Ecklonia stolonifera.
Marinedrugs 17 00108 g001
Marinedrugs 17 00108 g002 550
Figure 2. Concentration-dependent percentage of control agonist effect of eckol on dopamine D3 (A) and D4 (B) receptors.
Figure 2. Concentration-dependent percentage of control agonist effect of eckol on dopamine D3 (A) and D4 (B) receptors.
Marinedrugs 17 00108 g002
Marinedrugs 17 00108 g003 550
Figure 3. Molecular docking of the human dopamine D3 receptor (hD3R) with eckol along with positive controls (A). Chemical structures of dopamine (specific agonist), (+)-butaclamol (antagonist), and eckol are shown by the blue, black and orange sticks, respectively (A). Close-up of the binding site of eckol (B,C) showing the hD3R-ligand interaction.
Figure 3. Molecular docking of the human dopamine D3 receptor (hD3R) with eckol along with positive controls (A). Chemical structures of dopamine (specific agonist), (+)-butaclamol (antagonist), and eckol are shown by the blue, black and orange sticks, respectively (A). Close-up of the binding site of eckol (B,C) showing the hD3R-ligand interaction.
Marinedrugs 17 00108 g003
Marinedrugs 17 00108 g004 550
Figure 4. Molecular docking of human dopamine D4 receptor (hD4R) with eckol along with positive controls (A). Chemical structures of dopamine, CHEMBL332154, and eckol are shown by the blue, black, and orange sticks, respectively. Close-up of binding site of eckol showing the hD4R-ligand interaction (B,C).
Figure 4. Molecular docking of human dopamine D4 receptor (hD4R) with eckol along with positive controls (A). Chemical structures of dopamine, CHEMBL332154, and eckol are shown by the blue, black, and orange sticks, respectively. Close-up of binding site of eckol showing the hD4R-ligand interaction (B,C).
Marinedrugs 17 00108 g004
Marinedrugs 17 00108 g005 550
Figure 5. Dopamine D3 receptor-eckol complex embedded in the palmitoyl-oleoyl-phosphatidylcholine (POPC) membrane. For clarity, water molecules are not shown (A). Final snapshot of residues and water molecules interacting with eckol after 80 ns of molecular dynamics simulation. Interacting residues enclosed within square-boxes (B) represent additional interactions and within red circles represents conserved interactions compared to docking simulation.
Figure 5. Dopamine D3 receptor-eckol complex embedded in the palmitoyl-oleoyl-phosphatidylcholine (POPC) membrane. For clarity, water molecules are not shown (A). Final snapshot of residues and water molecules interacting with eckol after 80 ns of molecular dynamics simulation. Interacting residues enclosed within square-boxes (B) represent additional interactions and within red circles represents conserved interactions compared to docking simulation.
Marinedrugs 17 00108 g005
Marinedrugs 17 00108 g006 550
Figure 6. Enlarged image of the eckol inside the binding pocket after 80 ns of molecular dynamics simulation (A). RMSD values for the protein backbone (red) and non-hydrogen ligand molecule (blue) during the 80-ns molecular dynamics simulation (B). Distance between the center of mass of the benzene ring of Phe346 and one of the benzene rings of the eckol molecule during the 80-ns molecular dynamics simulation (C). Histogram of the distance between the center of mass of the benzene ring of Phe346 and one of the benzene rings of eckol molecule from 60 ns to 80 ns (D).
Figure 6. Enlarged image of the eckol inside the binding pocket after 80 ns of molecular dynamics simulation (A). RMSD values for the protein backbone (red) and non-hydrogen ligand molecule (blue) during the 80-ns molecular dynamics simulation (B). Distance between the center of mass of the benzene ring of Phe346 and one of the benzene rings of the eckol molecule during the 80-ns molecular dynamics simulation (C). Histogram of the distance between the center of mass of the benzene ring of Phe346 and one of the benzene rings of eckol molecule from 60 ns to 80 ns (D).
Marinedrugs 17 00108 g006
Table
Table 1. Agonist effect of eckol and reference compounds on various receptors.
Table 1. Agonist effect of eckol and reference compounds on various receptors.
Receptor% of Control Agonist ResponseEC50 a (μM)Reference Agonists of Respective Target Receptors EC50 (nM) b
25 μM50 μM
D1 (h) Dopamine−0.58 ± 2.46 e,f−2.77 ± 1.27 d‒dopamine36
D3 (h) Dopamine10.60 ± 4.16 d53.10 ± 6.67 c48.62 ± 3.21dopamine2.9
D4 (h) Dopamine36.55 ± 10.94 c54.66 ± 7.05 c42.55 ± 2.54dopamine3.3
M5 (h) Acetylcholine (muscarinic)0.38 ± 0.10 e0.39 ± 0.46 d‒acetylcholine3.8
NK1 (h) Tachykinin−2.32 ± 0.26 e,f−2.99 ± 0.21 d‒[Sar9, Met(O2)11]-SP0.094
V1A (h) Vasopressin/Oxytocin−8.91 ± 3.20 f−12.46 ± 0.51 e‒AVP0.11
5-HT1A (h) Serotonin−1.78 ± 0.45 e,f−3.04 ± 1.23 d‒serotonin3.1
a Concentration producing a half-maximal agonist response; b Concentration producing a 50% agonist response for respective receptors as reported by Eurofins Panlab; c–f Mean with different letters are significantly different with Duncan’s test at p < 0.05.
Table
Table 2. Antagonist effect of eckol and reference compounds on various receptors.
Table 2. Antagonist effect of eckol and reference compounds on various receptors.
Receptor% Inhibition of Control Agonist ResponseIC50 a (μM)Reference Antagonists of Respective Target Receptors IC50 (nM) b
25 μM50 μM
D1 (h) Dopamine11.55 ± 2.151.89 ± 1.62‒SCH 233900.5
D3 (h) Dopamine−9.0 ± 6.98−15.1 ± 2.51‒(+)-butaclamol16
D4 (h) Dopamine1.33 ± 1.70−3.33 ± 4.70‒clozapine49
M5 (h) Acetylcholine (muscarinic)1.0 ± 0.4−4.8 ± 2.25‒atropine0.33
NK1 (h) Tachykinin−11.35 ± 6.37−4.32 ± 3.33‒L 733,0600.21
V1A (h) Vasopressin/Oxytocin−13.46 ± 6.93−4.26 ± 11.06‒[d(CH2)5 1,Tyr(Me)2]-AVP0.05
5-HT1A (h) Serotonin6.17 ± 10.313.49 ± 4.33‒(S)-WAY-1006350.77
a Concentration producing a half-maximal inhibition of the control agonist response; b Concentration producing a 50% antagonist response for respective receptors as reported by Eurofins Panlab.
Table
Table 3. Binding sites and docking score of compounds in the human dopamine D3/D4 receptor (hD3R/hD4R).
Table 3. Binding sites and docking score of compounds in the human dopamine D3/D4 receptor (hD3R/hD4R).
TargetCompoundsBinding Energy (kcal/mol)No. of H-BondsH-Bond Interaction ResiduesHydrophobic Interacting ResiduesOthers
hD3RDopamine a (Agonist)−5.845Salt bridge: Asp110, O–H bond: Val111, Thr115, Ser196Alkyl: Val111, Cys114, π–Alkyl: Phe346
Rotigotine a (Agonist)−9.232Salt bridge: Asp110, C–H bond: Ser192Alkyl: Val111, π–Alkyl: Phe345, His349, Val107, Cys181, Val111, Cys114
Eticlopride a (Antagonist)−8.50 b3Salt bridge, O–H bond: Asp110, C–H bond: His349Alkyl: Val111, Cys114, Val189, π–Alkyl: Phe346, His349, Val111, Ile183, π–π T shaped: Phe345
(+)-Butaclamol a (Antagonist)−8.501Salt bridge: Asp110Alkyl: Val86, Val111, Cys114, π–Alkyl: Trp342, Phe346, π–π stacked: Phe345, π–Sigma: Thr369
Eckol−6.415O–H bond: Ile183, His349, Asp110, Val189π–Alkyl: Val189, Val107, Ile183, π–π T shaped: His349, π–Sigma: Thr369π–Sulfur: Cys114, π–lone pair: His349
hD4RDopamine c (Agonist)−5.683Salt bridge: Asp115, O–H bond: Ser196π–Alkyl: Cys119, π–π T shaped: Phe410, π–Sigma: Val116
Nemonapride c (Agonist)−11.82 d5Salt bridge, O–N bond: Asp115, C–H bond: Ser196, O–H bond: Tyr438Alkyl: Val193, π–Alkyl: Leu111, Cys185, π–π T shaped: Phe91, Phe410, π–Sigma: Val116π–Sulfur: Cys119, Amide– π stacked: Leu90, Phe91
CHEMBL332154 c (Antagonist)−9.425Salt bridge: Asp115, O–H bond: Asp115, Thr120, C–O bond: Cys185π–Alkyl: Val87, Cys185, Val116, Leu187, Cys119, π–π T shaped: Phe410, Phe411, His414, π–Sigma: Leu111, Val116
Eckol−6.464O–H bond: Tyr192, Asp115, Val193, Ser197π–Alkyl: Leu187, Val193, π–π T shaped: Phe410, His414π–Sulfur: Cys119, π–Cation: His414
a Positive ligand for D3R; b Root mean squared deviation (RMSD)value: 0.48 Å; c Positive ligand for D4R; d RMSD value: 0.21.
Table
Table 4. Absorption, distribution, metabolism, and excretion (ADME) characteristics of eckol isolated from Ecklonia stolonifera.
Table 4. Absorption, distribution, metabolism, and excretion (ADME) characteristics of eckol isolated from Ecklonia stolonifera.
CompoundMolecular Weight (g/mol)Log Po/w aPlasma Protein Binding bHuman Intestinal Absorption cIn Vivo Blood–Brain Barrier Penetration ([brain]/[blood]) d
Eckol372.2852.99100%55.60%0.25
a The log of the coefficient for solvent partitioning between 1-octanol and water; b <90%: weakly bound, >90%: strongly bound; c 0~20%: poorly absorbed, 20~70%: moderately absorbed, 70~100%: well absorbed; d <0.1: low absorption by the central nervous system, 0.1~2.0: moderate absorption, >2.0: high absorption.

Share and Cite

MDPI and ACS Style

Paudel, P.; Seong, S.H.; Wu, S.; Park, S.; Jung, H.A.; Choi, J.S. Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine D3/D4 Receptors. Mar. Drugs 2019, 17, 108. https://doi.org/10.3390/md17020108

AMA Style

Paudel P, Seong SH, Wu S, Park S, Jung HA, Choi JS. Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine D3/D4 Receptors. Marine Drugs. 2019; 17(2):108. https://doi.org/10.3390/md17020108

Chicago/Turabian Style

Paudel, Pradeep, Su Hui Seong, Sangwook Wu, Suhyun Park, Hyun Ah Jung, and Jae Sue Choi. 2019. "Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine D3/D4 Receptors" Marine Drugs 17, no. 2: 108. https://doi.org/10.3390/md17020108

APA Style

Paudel, P., Seong, S. H., Wu, S., Park, S., Jung, H. A., & Choi, J. S. (2019). Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine D3/D4 Receptors. Marine Drugs, 17(2), 108. https://doi.org/10.3390/md17020108

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop